First PARP inhibitor approved in prostate cancer (2020)
The FDA approved olaparib for men with HRR-mutated metastatic castration-resistant prostate cancer, based on the PROfound trial. It was the first time a PARP inhibitor, a drug class born in ovarian and breast cancer, reached prostate cancer patients.
Genetic testing for BRCA and related mutations became routine in advanced prostate cancer.
It opened the door to PARP inhibitor combinations that later moved the class earlier in treatment.
TALAPRO-3 continues that push, testing whether the same biology helps men at an earlier, hormone-sensitive stage.
